← Leaderboards
Hannelore Heemers
Cleveland Clinic Lerner Com-Cwru
$4,990,015
Attributed
$4,990,015
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $683.6K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,990,015 · 2
By mechanism
R01$4,990,015 · 2
Top collaborators
No co-investigators on record.
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Olga Cherepanova$2,012,500
- Jeffrey M Bhasin$64,862
- Carol Langford$15,734
- Kiran Bhaskar$6,515,945
Others in their field
Top investigators on “Therapeutic Intervention”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$297,163,567
- Leonard Freedman · Leidos Biomedical Research, Inc.$269,117,714
- Daniel R Kuritzkes · Brigham And Women'S Hospital$246,024,897
Research focus
Therapeutic InterventionModalityMalignant NeoplasmsPhenotypeMolecularProtein KinaseInsightMalignant Neoplasm Of ProstateMissionOverexpressionSignal TransductionDisease ProgressionEventFoundationsGene ExpressionInnovationLaboratoriesBenignAffectMediatingProstate Cancer TherapyProstate Cancer CellTargeted TreatmentProstate
Grant awards (16)
A novel determinant of prostate cancer growth$322,764
R01 · FY2025 · CA · contact PI
Toward Selective Androgen Deprivation by Targeting Androgen Activation of SRF$336,071
R01 · FY2024 · CA · contact PI
A novel determinant of prostate cancer growth$306,625
R01 · FY2024 · CA · contact PI
Toward Selective Androgen Deprivation by Targeting Androgen Activation of SRF$346,685
R01 · FY2023 · CA · contact PI
A novel determinant of prostate cancer growth$316,309
R01 · FY2023 · CA · contact PI
Toward Selective Androgen Deprivation by Targeting Androgen Activation of SRF$346,685
R01 · FY2022 · CA · contact PI
A novel determinant of prostate cancer growth$321,364
R01 · FY2022 · CA · contact PI
Toward Selective Androgen Deprivation by Targeting Androgen Activation of SRF$353,760
R01 · FY2021 · CA · contact PI
A novel determinant of prostate cancer growth$329,815
R01 · FY2021 · CA · contact PI
Toward Selective Androgen Deprivation by Targeting Androgen Activation of SRF$352,691
R01 · FY2020 · CA · contact PI
Towards selective androgen deprivation by targeting androgen activation of SRF$151,154
R01 · FY2019 · CA · contact PI
Towards selective androgen deprivation by targeting androgen activation of SRF$338,994
R01 · FY2018 · CA · contact PI
Towards selective androgen deprivation by targeting androgen activation of SRF$149,738
R01 · FY2017 · CA · contact PI
Towards selective androgen deprivation by targeting androgen activation of SRF$329,794
R01 · FY2016 · CA · contact PI
Towards selective androgen deprivation by targeting androgen activation of SRF$331,370
R01 · FY2015 · CA · contact PI
Towards selective androgen deprivation by targeting androgen activation of SRF$356,196
R01 · FY2014 · CA · contact PI